BLUE BELL, Pa., May 17, 2011 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that the company will highlight its DNA vaccines and electroporation delivery technology at the 14th Annual Meeting of the American Society of Gene & Cell Therapy to be held May 18-21 in Seattle, Washington at the Washington State Convention & Trade Center. Several of Inovio's scientists will make podium presentations and poster presentations:
Oral Presentation: "Induction of Strong Cellular and Humoral Immune Responses Following Immunotherapy of Post-LEEP CIN 2/3 with HPV 16 & 18 E6/E7 DNA Vaccines"Wednesday, May 18, 4:30 pm
Oral Presentation: "Piezoelectric Permeabilization of Mammalian Dermal Tissue for In Vivo DNA Delivery Leads to Enhanced Protein Expression and Increased Immunogenicity"Saturday, May 21, 11:15 am
Poster Presentation: "Combining Linear Expression Cassette Technology with Novel Electroporation Techniques to Deliver Influenza DNA Vaccines" Friday, May 20, 4:40 pm
Poster Presentation: "Co-Delivery of PSA and PSMA DNA Vaccines with Electroporation Induces Potent Immune Responses" Friday, May 20, 4:40 pmAbout the American Society of Gene & Cell TherapyThe world's leading researchers in gene and cell therapy will present new findings at the American Society of Gene & Cell Therapy 14th Annual Meeting attended by more than 2,000 scientists, and postdoctoral fellows from around the world. The American Society of Gene & Cell Therapy (ASGCT) is a professional non-profit medical and scientific organization dedicated to the understanding, development and application of genetic and cellular therapies and the promotion of professional and public education in the field.
About Inovio Pharmaceuticals, Inc. Inovio is developing a new generation of vaccines, called DNA vaccines, to treat and prevent cancers and infectious diseases. Its SynCon™ vaccines are designed to provide broad cross-strain protection against known as well as newly emergent strains of pathogens such as influenza. These vaccines, in combination with Inovio's proprietary electroporation delivery devices, have been shown to be safe and generate significant immune responses. Inovio clinical programs include three Phase II studies for vaccines treating cervical dysplasia/cancer, hepatitis C virus, and leukemia. Other clinical programs target influenza (preventive) and HIV (preventive and therapeutic). Inovio partners and collaborators include the University of Pennsylvania, Merck, ChronTech, National Cancer Institute, U.S. Military HIV Research Program, NIH, HIV Vaccines Trial Network, University of Southampton, and PATH Malaria Vaccine Initiative. More information is available at www.inovio.com.
This press release contains certain forward-looking statements relating to our business, including our plans to develop electroporation-based drug and gene delivery technologies and DNA vaccines and our capital resources. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in pre-clinical studies, clinical trials and product development programs (including, but not limited to, the fact that pre-clinical and clinical results referenced in this release may not be indicative of results achievable in other trials or for other indications, that the studies or trials may not be successful or achieve the results desired, that results from one study may not necessarily be reflected or supported by the results of other similar studies and that results from an animal study may not be indicative of results achievable in human studies), the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable DNA vaccines, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the conditions targeted by the company or its collaborators, including alternatives that may be more efficacious or cost-effective than any therapy or treatment that the company and its collaborators hope to develop, evaluation of potential opportunities, issues involving product liability, issues involving patents and whether they or licenses to them will provide the company with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether the company can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of the company's technology by potential corporate or other partners or collaborators, capital market conditions, our ability to successfully integrate Inovio and VGX Pharmaceuticals, the impact of government healthcare proposals and other factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2010, our Form 10-Q for the three months ended March 31, 2011, and other regulatory filings from time to time. There can be no assurance that any product in Inovio's pipeline will be successfully developed or manufactured, that final results of clinical studies will be supportive of regulatory approvals required to market licensed products, or that any of the forward-looking information provided herein will be proven accurate.
|SOURCE Inovio Pharmaceuticals, Inc.|
Copyright©2010 PR Newswire.
All rights reserved